| Targeting human telomerase in cancer therapy. | |
| | |
MedLine Citation:
|
PMID: 12678725 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Telomerase is a specialized RNA template-containing reverse transcriptase that mediates telomere repeat synthesis at chromosome ends. The maintenance of telomere length and integrity is essential for cell survival. Telomerase is active in most immortal and tumor cells, whereas the majority of normal human cells demonstrate no detectable activity and undergo telomere shortening. The identification of a possible role for telomerase in cellular aging and cancer has led to numerous studies designed to characterize this ribonucleoprotein enzyme. Inhibiting telomerase activity in immortal human cells reduces cellular proliferative capacity and can lead to cell death. Identifying mechanisms to specifically inhibit telomerase activity in malignant cells could thus be of great therapeutic value in the treatment of cancer. In this review, we summarize the current understanding of the mechanism of action of human telomerase. The biochemical characterization of telomerase is necessary for the design and evaluation of antitelomerase therapies. Different strategies are currently under investigation to design inhibitors that target the reverse transcriptase and RNA components of the telomerase complex. Recent advances in the design of these inhibitors and their properties are discussed. |
| | |
Authors:
|
Sylvain Huard; Chantal Autexier |
Related Documents
:
|
879045 - Observation on the morphological heterogeneity of wi-38 cells. 8325355 - Accumulation of a senescence factor in yeast cells. 19577445 - Wogonin, an active compound in scutellaria baicalensis, induces apoptosis and reduces t... 19458325 - Accumulation of large protein fragments in prematurely senescent arpe-19 cells. 16727715 - Factors affecting cell viability during bisection of bovine embryos. 10399275 - L-asparaginase ii of saccharomyces cerevisiae. activity profile during growth using an ... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Current medicinal chemistry. Anti-cancer agents Volume: 2 ISSN: 1568-0118 ISO Abbreviation: Curr Med Chem Anticancer Agents Publication Date: 2002 Sep |
Date Detail:
|
Created Date: 2003-04-07 Completed Date: 2003-06-10 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 101123597 Medline TA: Curr Med Chem Anticancer Agents Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 577-87 Citation Subset: IM |
Affiliation:
|
Department of Anatomy and Cell Biology, McGill University, and Bloomfield Centre for Research in Aging, Lady Davis Institute for Medical Research, The Sir Mortimer B. Davis Jewish General Hospital, 3755 Côte Ste. Catherine Road, Montréal, Québec, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antineoplastic Agents / chemistry, pharmacology*, therapeutic use Catalytic Domain / drug effects Drug Design Enzyme Inhibitors / chemistry, pharmacology, therapeutic use* Humans Neoplasms / drug therapy, enzymology, pathology Oligonucleotides / chemistry, pharmacology, therapeutic use Telomerase / antagonists & inhibitors*, chemistry, metabolism Telomere / chemistry, metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Enzyme Inhibitors; 0/Oligonucleotides; EC 2.7.7.49/Telomerase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Telomerase inhibitors as anticancer therapy.
Next Document: The 'other' telomerase inhibitors: non-G-quadruplex interactive agent, non-antisense, non-reverse tr...